Leads Biolabs' partner Dianthus Therapeutics has prioritized LBL-047 for clinical development targeting Sjögren's disease, systemic lupus erythematosus, and dermatomyositis, addressing high unmet medical needs. LBL-047 is a bifunctional fusion protein designed to reduce immune system overactivity by targeting key pathways in autoimmune diseases. A Phase 1 trial started in China in December 2025, with initial results expected in the second half of 2026. Dianthus recently raised $719 million to support global development, aiming to advance LBL-047 as a potential first-line biologic therapy with convenient dosing.
STMicroelectronics announced a $1.5 billion issuance of new convertible senior bonds in two tranches, with maturities of 5 and 7 years, alongside the early repayment of $750 million of zero-coupon convertible bonds due in 2027. The new bonds offer fi...
Regentis Biomaterials shares surged over 500% intraday before falling 9.15% in after-hours trading following the company's announcement that it withdrew its Registration Statement for a public offering. The regenerative medicine firm decided not to p...
Elon Musk's SpaceX recently went public, raising questions about a potential IPO for its Starlink subsidiary. Data from prediction market Kalshi shows only a 7-10% chance of a Starlink IPO announcement before mid-2027. Meanwhile, Musk predicts SpaceX...
Goodfirms has published its 2026 rankings of top technology service providers across six categories: mobile app, software, web development, digital marketing, SEO, and AI development. These rankings are based on over 1.2 million verified client revie...
Alvotech announced a $152 million public offering and concurrent private placement of ordinary shares priced at $3.75 each. The public offering includes 22.7 million shares, with an option for underwriters to buy an additional 3.4 million shares. The...
